lansoprazole has been researched along with tacrolimus in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 14 (60.87) | 29.6817 |
| 2010's | 8 (34.78) | 24.3611 |
| 2020's | 1 (4.35) | 2.80 |
| Authors | Studies |
|---|---|
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF | 1 |
| Fukao, K; Homma, M; Itagaki, F; Kohda, Y; Yuzawa, K | 2 |
| Inui, K; Ito, N; Motohashi, H; Ogawa, O; Okuda, M; Takahashi, K; Yamamoto, S; Yonezawa, A | 1 |
| Homma, M; Itagaki, F; Kohda, Y; Naito, S; Nishimura, M; Ohkohchi, N; Ueda, N; Yuzawa, K | 1 |
| Habuchi, T; Kagaya, H; Miura, M; Sagae, Y; Satoh, S; Suzuki, T; Tada, H | 1 |
| Habuchi, T; Inoue, K; Ishikawa, M; Kagaya, H; Kanno, S; Miura, M; Sagae, Y; Saito, M; Satoh, S; Suzuki, T; Tada, H | 1 |
| Habuchi, T; Inoue, K; Itoh, Y; Kagaya, H; Miura, M; Satoh, S; Suzuki, T; Tada, H; Tanaka, Y | 1 |
| Habuchi, T; Inoue, K; Kagaya, H; Miura, M; Sagae, Y; Satoh, S; Suzuki, T; Tada, H | 1 |
| Habuchi, T; Inoue, K; Kagaya, H; Miura, M; Saito, M; Satoh, S; Suzuki, T | 1 |
| Hosohata, K; Inui, K; Katsura, T; Masuda, S; Ogura, Y; Oike, F; Takada, Y; Uemoto, S | 1 |
| Egawa, H; Hosohata, K; Inui, K; Kaido, T; Katsura, T; Masuda, S; Ogura, Y; Oike, F; Takada, Y; Uemoto, S | 1 |
| Habuchi, T; Hayakari, M; Kagaya, H; Miura, M; Niioka, T; Saito, M; Satoh, S | 1 |
| Fujieda, A; Iwamoto, T; Katayama, N; Monma, F; Nakatani, K; Okuda, M | 1 |
| Hanafusa, T; Hata, K; Hirano-Kuwata, S; Isoda, K; Kotani, T; Makino, S; Shoda, T; Takeuchi, T; Yoshida, S | 1 |
| Aydin, F; Caliskan, Y; Ciftci, HS; Demir, E; Karadeniz, MS; Nane, I; Oguz, FS; Tefik, T; Turkmen, A; Yazıcı, H | 1 |
2 review(s) available for lansoprazole and tacrolimus
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Neoplastic Stem Cells | 2022 |
4 trial(s) available for lansoprazole and tacrolimus
| Article | Year |
|---|---|
Effect of lansoprazole and rabeprazole on tacrolimus pharmacokinetics in healthy volunteers with CYP2C19 mutations.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Anti-Ulcer Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Cross-Over Studies; Cytochrome P-450 CYP2C19; Drug Interactions; Female; Genotype; Humans; Immunosuppressive Agents; Lansoprazole; Male; Metabolic Clearance Rate; Middle Aged; Mixed Function Oxygenases; Omeprazole; Rabeprazole; Tacrolimus | 2004 |
Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Cytochrome P-450 CYP2C19; Dexlansoprazole; Humans; Immunosuppressive Agents; Kidney Transplantation; Kinetics; Lansoprazole; Mixed Function Oxygenases; Models, Molecular; Molecular Structure; Omeprazole; Rabeprazole; Stereoisomerism; Substrate Specificity; Tacrolimus | 2005 |
Influence of ABCB1 C3435T polymorphism on the pharmacokinetics of lansoprazole and gastroesophageal symptoms in Japanese renal transplant recipients classified as CYP2C19 extensive metabolizers and treated with tacrolimus.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Alleles; Anti-Ulcer Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Asian People; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytochrome P-450 CYP2C19; Dexlansoprazole; Female; Gastroesophageal Reflux; Genotype; Half-Life; Humans; Immunosuppressive Agents; Japan; Kidney Transplantation; Lansoprazole; Male; Middle Aged; Mixed Function Oxygenases; Organic Anion Transporters; Polymorphism, Genetic; Tacrolimus | 2006 |
Influence of rabeprazole and lansoprazole on the pharmacokinetics of tacrolimus in relation to CYP2C19, CYP3A5 and MDR1 polymorphisms in renal transplant recipients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Female; Genes, MDR; Humans; Immunosuppressive Agents; Kidney Transplantation; Lansoprazole; Male; Middle Aged; Mixed Function Oxygenases; Polymorphism, Genetic; Rabeprazole; Tacrolimus | 2007 |
17 other study(ies) available for lansoprazole and tacrolimus
| Article | Year |
|---|---|
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Effects of lansoprazole and rabeprazole on tacrolimus blood concentration: case of a renal transplant recipient with CYP2C19 gene mutation.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Exons; Female; Humans; Immunosuppressive Agents; Lansoprazole; Middle Aged; Mixed Function Oxygenases; Mutation; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Tacrolimus | 2002 |
Drug interaction of tacrolimus and proton pump inhibitors in renal transplant recipients with CYP2C19 gene mutation.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Cytochrome P-450 CYP2C19; Drug Interactions; Famotidine; Female; Humans; Immunosuppressive Agents; Kidney Transplantation; Lansoprazole; Male; Middle Aged; Mixed Function Oxygenases; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Tacrolimus | 2002 |
Lansoprazole-tacrolimus interaction in Japanese transplant recipient with CYP2C19 polymorphism.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Drug Synergism; Humans; Immunosuppressive Agents; Kidney Transplantation; Lansoprazole; Male; Mixed Function Oxygenases; Omeprazole; Polymorphism, Genetic; Tacrolimus | 2004 |
Influence of cytochrome P450 (CYP) 3A5 polymorphisms on the pharmacokinetics of lansoprazole enantiomers in CYP2C19 extensive metaboliser renal transplant recipients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Infective Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Immunosuppressive Agents; Kidney Transplantation; Lansoprazole; Mixed Function Oxygenases; Mycophenolic Acid; Polymorphism, Genetic; Stereoisomerism; Tacrolimus | 2007 |
Influence of lansoprazole and rabeprazole on mycophenolic acid pharmacokinetics one year after renal transplantation.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Female; Genotype; Humans; Immunosuppressive Agents; Kidney Transplantation; Lansoprazole; Male; Middle Aged; Mixed Function Oxygenases; Mycophenolic Acid; Polymorphism, Single Nucleotide; Prednisolone; Rabeprazole; Retrospective Studies; Tacrolimus | 2008 |
Interaction between tacrolimus and lansoprazole, but not rabeprazole in living-donor liver transplant patients with defects of CYP2C19 and CYP3A5.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adjuvants, Immunologic; Adult; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Drug Interactions; Female; Humans; Lansoprazole; Liver Transplantation; Living Donors; Male; Middle Aged; Mixed Function Oxygenases; Rabeprazole; Tacrolimus | 2008 |
Impact of intestinal CYP2C19 genotypes on the interaction between tacrolimus and omeprazole, but not lansoprazole, in adult living-donor liver transplant patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Drug Interactions; Female; Genotype; Humans; Immunosuppressive Agents; Lansoprazole; Liver Transplantation; Living Donors; Male; Middle Aged; Omeprazole; Tacrolimus | 2009 |
Pharmacogenetic determinants for interindividual difference of tacrolimus pharmacokinetics 1 year after renal transplantation.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Drug Interactions; Female; Genotype; Humans; Immunosuppressive Agents; Kidney Transplantation; Lansoprazole; Male; Pharmacogenetics; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Rabeprazole; Tacrolimus; Time Factors | 2011 |
Hepatic drug interaction between tacrolimus and lansoprazole in a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A5 heterozygous mutations.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Antifungal Agents; Aryl Hydrocarbon Hydroxylases; Bone Marrow Transplantation; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Humans; Immunosuppressive Agents; Infusions, Intravenous; Lansoprazole; Liver; Male; Mutation; Pyrimidines; Tacrolimus; Triazoles; Voriconazole | 2011 |
The proton pump inhibitor lansoprazole, but not rabeprazole, the increased blood concentrations of calcineurin inhibitors in Japanese patients with connective tissue diseases.
Topics: Calcineurin Inhibitors; Connective Tissue Diseases; Cyclosporine; Cytochrome P-450 CYP2C19; Drug Interactions; Female; Gastrointestinal Diseases; Genotype; Humans; Lansoprazole; Male; Middle Aged; Polymorphism, Genetic; Proton Pump Inhibitors; Rabeprazole; Retrospective Studies; Tacrolimus | 2014 |
Influence of Proton Pump Inhibitors on Mycophenolic Acid Pharmacokinetics in Patients With Renal Transplantation and the Relationship With Cytochrome 2C19 Gene Polymorphism.
Topics: Adult; Cytochrome P-450 CYP2C19; Drug Interactions; Drug Therapy, Combination; Female; Genotype; Humans; Immunosuppressive Agents; Kidney Transplantation; Lansoprazole; Male; Middle Aged; Mycophenolic Acid; Polymorphism, Restriction Fragment Length; Polymorphism, Single Nucleotide; Proton Pump Inhibitors; Rabeprazole; Retrospective Studies; Tacrolimus | 2017 |